Gepant treAtments: EffectIveNess and tolERability (GAINER)

Sponsor
University of Florence
Study ID
NCT05903027
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.

Key Dates

Start date
Jun 15, 2023
Status verified
Jan 2026
Primary completion
Jun 15, 2024
Completion
Sep 15, 2026

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Episodic migraine
    Patients affected by an episodic pattern migraine(\< 15 monthly headache days) with or without aura according to ICHD-III criteria.
  • Arm: Chronic migraine
    Patients affected by chronic migraine according to ICHD-III criteria.

Primary Outcome Measure

Headache pain freedom at 2 hours post-dose during the first attack [ Time Frame: 2 hours post-dose ]

Central Contacts

Related Studies